pharmaphorum Podcast

Anlnylam’s Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company’s work in gene-silencing and how it could offer a route to target the current coronavirus pandemic.

Novartis’ Steven Baert joined the pharmaphorum podcast for episode 22 to discuss how COVID-19 will change the face

Harvard University launched LabXchange in January and the free science education platform has acquired new resonance during the

The COVID-19 pandemic has forced significant changes on the pharmaceutical industry as companies scramble to protect employees, ensure

Voice technology like Amazon’s Alexa is taking some big steps forward in healthcare and in the pharmaceutical world

One of the biggest barriers to applying precision medicine to clinical trials and patient engagement is getting different

In the first pharmaphorum podcast of 2020 Roche’s Conor Megaw talks about his company’s approach to big data

Pfizer’s Dr Olivia Ashman joined me for episode 16 of the pharmaphorum podcast, which focuses on the UK

Episode 15 of the pharmaphorum podcast marked a return visit for leading life sciences industry authority Professor Brian

This episode of the pharmaphorum podcast focuses on lung cancer, with AstraZeneca’s VP, Global Franchise Head, Tagrisso TDR

For episode 13 of the pharmaphorum podcast I went to AstraZeneca’s London base to meet Paul Naish, who’s

The UK environment for drug discovery, the impact of artificial intelligence (AI) on medicines research and the role of complex cell models were all on the agenda for episode 12 of the pharmaphorum podcast. On it I spoke with Chris Molloy, who’s CEO at the UK’s Medicines Discovery Catapult, about the Catapult’s State of the Discovery Nation publication, a joint report with the UK’s biotech trade b...

For episode 11 of the pharmaphorum podcast our CEO and founder Dr Paul Tunnah took the helm to record a special roundtable episode in Philadelphia with the International AIDS Vaccine Initiative (IAVI).

For episode 10 of the pharmaphorum podcast I spoke to Nicola Redfern, who’s general manager at bluebird bio in the UK. The Cambridge, Massachusetts-based company has gone from being a gene therapy start-up to having three potential blockbusters on its books, with a CAR-T cancer medicine and potential treatments for a type of sickle-cell disease and a rare and deadly genetic brain disease.

Re-engineered honey has proved to be a novel and successful development for Matoke Pharma, as well as a crucial step on the UK biotech company’s plans to target antimicrobial resistance (AMR). In episode 9 of the pharmaphorum podcast Alan Westwood explains the research behind Matoke’s SurgihoneyRO, an antimicrobial wound gel that has a CE mark in Europe, and how the company is taking that product’...

Digital innovation and disruption in healthcare are the subject of this episode of the pharmaphorum podcast, for which I visited GlaxoSmithKline at their Stockley Park base to speak with Kai Gait, a senior global digital strategy director at the company.

For episode 7 of the pharmaphorum podcast I spoke to Ipsen’s Philippe Picaut about neurotoxin research, with a particular focus on Botulinum neurotoxins.

The pharmaphorum podcast’s first episode of 2019 features Professor Brian D Smith on what makes a modern, and successful, medical marketing team.

For episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The Wellcome Collection in London to talk about the UK biotech he co-founded, its strategy and bringing innovation to life through Blueberry’s nanomedicine approach.

In episode 4 of the podcast pharmaphorum talked to Dr Joe Wiley, CEO of UK-based biopharmaceutical company Amryt Pharma, about its strategy and work in the rare diseases and gene therapy space.

For episode 3 of the pharmaphorum podcast Dominic Tyer went to the UK headquarters of Sandoz to meet the head of the company’s UK specialty business Kavya Gopal.

In episode 2 of the podcast pharmaphorum talked to the CEO of Infirst Healthcare Manfred Scheske about how he’s seen the consumer health sector develop.